drugset / Trial / NCT04340596
Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption
Phase 1
Active not recruiting
118 enrolled
National Institute of Allergy and Infectious Diseases (NIAID)
ImmunityBio, Inc. · collabRockefeller University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of N-803, an IL-15 superagonist, with or without combination broadly neutralizing antibodies (bNAbs), to induce HIV-1 control during analytic treatment interruption (ATI).
Timeline
- Start
- 2021-05-21
- Primary completion
- 2026-06-30
- Completion
- 2026-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | N-803 | Protein / enzyme biologic | 6 ug/kg | Subcutaneous |
| Subject | VRC07-523LS | Monoclonal antibody | 20 mg/kg | Intravenous |
| Subject | Zinlirvimab | Monoclonal antibody | 30 mg/kg | Intravenous |